Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

2014248 citationsJournal Articlegold Open Access

Authors

Clinicaltrials.gov NCT01131676.

Good health and well-being

Published in: Cardiovascular Diabetology

Volume 13, Issue 1, pp. 102-102

Field-Weighted Citation Impact: 18.02